多西紫杉醇加强的松或米托蒽醌加强的松治疗晚期前列腺癌

50 Studies Every Urologist Should Know Pub Date : 2021-02-01 DOI:10.1093/MED/9780190655341.003.0015

J. Zabell

{"title":"多西紫杉醇加强的松或米托蒽醌加强的松治疗晚期前列腺癌","authors":"J. Zabell","doi":"10.1093/MED/9780190655341.003.0015","DOIUrl":null,"url":null,"abstract":"This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.","PeriodicalId":435097,"journal":{"name":"50 Studies Every Urologist Should Know","volume":"10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"21","resultStr":"{\"title\":\"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer\",\"authors\":\"J. Zabell\",\"doi\":\"10.1093/MED/9780190655341.003.0015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.\",\"PeriodicalId\":435097,\"journal\":{\"name\":\"50 Studies Every Urologist Should Know\",\"volume\":\"10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"21\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"50 Studies Every Urologist Should Know\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/MED/9780190655341.003.0015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"50 Studies Every Urologist Should Know","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/MED/9780190655341.003.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 21

摘要

本章总结了具有里程碑意义的TAX 327试验的结果，该试验在接受多西他赛(每周一次或每3周一次)或米托蒽醌(每3周一次)治疗的去势难治性前列腺癌男性患者中进行。研究发现，接受多西他赛治疗的男性总体生存率提高，生活质量提高，副作用相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer

This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

50 Studies Every Urologist Should Know

自引率

0.00%

发文量